$CELG Form 8-K

0
434

Form 8-K for CELGENE CORP /DE/


17-Feb-2017

Other Events

ITEM 8.01 OTHER EVENTSOn February 17, 2017, Celgene Corporation issued a press release announcing certain results of its phase 3 SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis. Attached hereto and incorporated herein by reference as Exhibit 99.1 is the press release announcement.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here